Listen "Building the Future of Brain Health: Neuroscience Drug Development with Novartis’ Dr. Norman Putzki"
Episode Synopsis
In this episode, Ayesha speaks with Norman Putzki, MD, Senior Vice President and Global Development Head of Neuroscience and Gene Therapy at Novartis, about the complexities and real-world challenges of bringing new therapies to patients with neurological diseases.
Dr. Putzki discusses the challenges and opportunities in developing treatments for complex brain disorders, and how gene therapy is being applied in neurological disease.
Dr. Putzki transitioned from an academic career in clinical neurology, with a focus on diseases like multiple sclerosis (MS), to the pharmaceutical industry in 2010. Since then, he has taken on leadership roles in both medical and development functions, first at Biogen and later at Novartis, where he currently leads global development efforts in neuroscience and gene therapy.
During his tenure at Novartis, he has been leading teams around the globe to various new indications, approvals and launches within the neuroscience portfolio.
Dr. Putzki received his PhD from Essen University in Germany and completed residency training in Internal Medicine and Neurology in Essen, University College London (Institute of Neurology Queen’s Square) and University of Berne (Switzerland). Dr. Putzki is an author/co-author of more than 50 peer reviewed publications and has authored 4 books. He is a fellow of the American Academy of Neurology.
Tune into the episode to learn more about the current landscape of drug development in neuroscience and neurological diseases — from research and strategy to execution on a global scale.
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media
Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Dr. Putzki discusses the challenges and opportunities in developing treatments for complex brain disorders, and how gene therapy is being applied in neurological disease.
Dr. Putzki transitioned from an academic career in clinical neurology, with a focus on diseases like multiple sclerosis (MS), to the pharmaceutical industry in 2010. Since then, he has taken on leadership roles in both medical and development functions, first at Biogen and later at Novartis, where he currently leads global development efforts in neuroscience and gene therapy.
During his tenure at Novartis, he has been leading teams around the globe to various new indications, approvals and launches within the neuroscience portfolio.
Dr. Putzki received his PhD from Essen University in Germany and completed residency training in Internal Medicine and Neurology in Essen, University College London (Institute of Neurology Queen’s Square) and University of Berne (Switzerland). Dr. Putzki is an author/co-author of more than 50 peer reviewed publications and has authored 4 books. He is a fellow of the American Academy of Neurology.
Tune into the episode to learn more about the current landscape of drug development in neuroscience and neurological diseases — from research and strategy to execution on a global scale.
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media
Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
More episodes of the podcast Xtalks Life Science Podcast
Exploring the Future of Cannabinoid & Psychedelic Therapies with Joel Latham of Incannex Healthcare
30/09/2025
Bridging Aesthetics and Therapeutics in Dermatology with Galderma’s Dr. Bill Andriopoulos
03/09/2025
Exploring Immunomodulation Without Immunosuppression with Artax Biopharma’s Dr. Rob Armstrong
19/08/2025